Valneva SE (VALN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valneva SE ("Valneva” or the "Company") (NYSE: VALN). The investigation concerns whether Valneva and certain of its officers and/or directors have violated federal securities laws.
On September 13, 2021, Valneva issued a press release “announc[ing] that it has received a termination notice from the UK Government (‘HMG’) in relation to the Supply Agreement for its COVID-19 vaccine candidate, VLA2001.” The press release further advised investors that “[t]he contract provides HMG with the right to terminate” and stated that “HMG has alleged that the Company is in breach of its obligations under the Supply Agreement, but the Company strenuously denies this.” On this news, Valneva’s American Depositary Receipt (“ADR”) price fell $18.65 per share, or 39.85%, to close at $28.15 per share on September 13, 2021.
If you are aware of any facts relating to this investigation, or purchased Valneva shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.